The Psilocybin Mushroom Story Could be the Next Big Investment Boom

Financialnewsmedia.com News Commentary

PALM BEACH, Florida, Oct. 10, 2019 /PRNewswire/ -- As the cannabis market booms, another drug may soon follow in its footsteps -- psilocybin mushrooms. Already, we're seeing a groundswell of interest. In fact, activists in California are working on getting its decriminalization added to the 2020 ballot. The proposed amendment – called the California Psilocybin Decriminalization Initiative — would revise state drug laws to decriminalize the "personal possession, storage, use, cultivation, manufacturing, distribution in personal possession amounts, according to Marijuana Moment. Better, the U.S. FDA already granted 'breakthrough status' to COMPASS Pathways' psilocybin-assisted therapy in October 2018, which allows the FDA assist in the development of a promising drug to treat serious illnesses. In addition, researchers at New York University found psilocybin mushrooms caused a 'rapid and sustained' reduction in anxiety and depression in patients with cancer," as reported by the Financial Post. As excitement builds, it's opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), GW Pharmaceuticals (NASDAQ:GWPH), Tilray Inc. (NASDAQ:TLRY), Aphria Inc. (NYSE:APHA) (TSX:APHA), and The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF).

The Yield Growth Corp.(CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS:The Yield Growth Corp. just announced that its wholly owned subsidiary Flourish Mushroom Labs Inc. has completed the acquisition, announced on September 24, 2019, of a catalogue of mushroom formulas as the foundation of a mushroom edibles business. The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer's choice. The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees. "Learning and memory are the core cognitive functions of the human brain," says Penny White, Yield CEO." With a rapid decline of age affecting the population cognitive deficit is leading to many neurological diseases. Flourish recognizes the early prevention needed for declining learning and memory to conduct research into creating edible products combining the mushroom medicine for a broad potential market." Included in the acquisition is know-how and research related to edible mushrooms that could be used in the formulations and various health benefits that can accrue to people eating those mushrooms, as determined by researching data published from clinical trials and from knowledge of Chinese, Tibetan and Ayurvedic medicine. The varieties of mushrooms to be used in the formulations include Lion's Mane, Turkey Tail, Reishi, Shitake, Chagas, Cordyceps and other wild varietals. The research and data on health benefits are included in the acquisition by Flourish. Flourish purchased the formulations and all know-how and data related to the formulations with the issuance of 120,000 common shares of Yield Growth at a deemed value of $0.25 per share.